{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:23:52Z","timestamp":1769599432117,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"DOI":"10.7759\/cureus.102423","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:03:52Z","timestamp":1769547832000},"source":"Crossref","is-referenced-by-count":0,"title":["Linitis Plastica in a Patient With a BRCA2 Mutation: A Case Report"],"prefix":"10.7759","author":[{"given":"Selina","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surabhi","family":"Amar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-017-1187-3","article-title":"The significance of a nineteenth century definition in the era of genomics: linitis plastica","volume":"15","author":"Agnes A","year":"2017","unstructured":"Agnes A, Estrella JS, Badgwell B. The significance of a nineteenth century definition in the era of genomics: linitis plastica. World J Surg Oncol. 2017, 15:123. 10.1186\/s12957-017-1187-3","journal-title":"World J Surg Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5946\/ce.2016.057","article-title":"Borrmann type 4 advanced gastric cancer: focus on the development of scirrhous gastric cancer","volume":"49","author":"Jung K","year":"2016","unstructured":"Jung K, Park MI, Kim SE, Park SJ. Borrmann type 4 advanced gastric cancer: focus on the development of scirrhous gastric cancer. Clin Endosc. 2016, 49:336-45. 10.5946\/ce.2016.057","journal-title":"Clin Endosc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914680","article-title":"The genomic signatures of linitis plastica signal the entrance into a new era: novel approaches for diagnosis and treatment","volume":"24","author":"Christodoulidis G","year":"2023","unstructured":"Christodoulidis G, Koumarelas KE, Kouliou MN, Samara M, Thodou E, Zacharoulis D. The genomic signatures of linitis plastica signal the entrance into a new era: novel approaches for diagnosis and treatment. Int J Mol Sci. 2023, 24:14680. 10.3390\/ijms241914680","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-019-04422-7","article-title":"Linitis plastica: a distinct type of gastric cancer","volume":"24","author":"Ikoma N","year":"2020","unstructured":"Ikoma N, Agnes A, Chen HC, et al.. Linitis plastica: a distinct type of gastric cancer. J Gastrointest Surg. 2020, 24:1018-25. 10.1007\/s11605-019-04422-7","journal-title":"J Gastrointest Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16303","article-title":"Gastric linitis plastica: clinical characteristics and outcomes from the National Cancer Database","volume":"43","author":"Ayub A","year":"2023","unstructured":"Ayub A, Naeem B, Perez A, Tyler D, Klimberg VS. Gastric linitis plastica: clinical characteristics and outcomes from the National Cancer Database. Anticancer Res. 2023, 43:1543-8. 10.21873\/anticanres.16303","journal-title":"Anticancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-022-01353-2","article-title":"Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica","volume":"26","author":"Liu Z","year":"2023","unstructured":"Liu Z, Hong LL, Zheng JS, et al.. Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica. Gastric Cancer. 2023, 26:203-19. 10.1007\/s10120-022-01353-2","journal-title":"Gastric Cancer"},{"key":"ref8","unstructured":"Genetic\/familial high-risk assessment. colorectal, endometrial, and gastric. (2025). Accessed: July 22, 2025: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_ceg.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-009-9463-3","article-title":"A comprehensive analysis of common genetic variation in MUC1, MUC5AC, MUC6 genes and risk of stomach cancer","volume":"21","author":"Jia Y","year":"2010","unstructured":"Jia Y, Persson C, Hou L, et al.. A comprehensive analysis of common genetic variation in MUC1, MUC5AC, MUC6 genes and risk of stomach cancer. Cancer Causes Control. 2010, 21:313-21. 10.1007\/s10552-009-9463-3","journal-title":"Cancer Causes Control"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2019.07.02","article-title":"Genetics of gastric cancer: what do we know about the genetic risks?","volume":"4","author":"Slavin TP","year":"2019","unstructured":"Slavin TP, Weitzel JN, Neuhausen SL, Schrader KA, Oliveira C, Karam R. Genetics of gastric cancer: what do we know about the genetic risks?. Transl Gastroenterol Hepatol. 2019, 4:55. 10.21037\/tgh.2019.07.02","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","unstructured":"Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014, 513.202-9. 10.1038\/nature13480","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016600","article-title":"Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins","volume":"7","author":"Prakash R","year":"2015","unstructured":"Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015, 7:016600. 10.1101\/cshperspect.a016600","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235953","article-title":"Gastric cancer risk and pathogenesis in BRCA1 and BRCA2 carriers","volume":"14","author":"Buckley KH","year":"2022","unstructured":"Buckley KH, Niccum BA, Maxwell KN, Katona BW. Gastric cancer risk and pathogenesis in BRCA1 and BRCA2 carriers. Cancers (Basel). 2022, 14:5953. 10.3390\/cancers14235953","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.0476","article-title":"Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants","volume":"8","author":"Momozawa Y","year":"2022","unstructured":"Momozawa Y, Sasai R, Usui Y, et al.. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022, 8:871-8. 10.1001\/jamaoncol.2022.0476","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57090905","article-title":"BRCA genes and related cancers: a meta-analysis from epidemiological cohort studies","volume":"57","author":"Lee YC","year":"2021","unstructured":"Lee YC, Lee YL, Li CY. BRCA genes and related cancers: a meta-analysis from epidemiological cohort studies. Medicina (Kaunas). 2021, 57:905. 10.3390\/medicina57090905","journal-title":"Medicina (Kaunas)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-020-00158-5","article-title":"A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays","volume":"5","author":"Biswas K","year":"2020","unstructured":"Biswas K, Lipton GB, Stauffer S, et al.. A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays. NPJ Genom Med. 2020, 5:52. 10.1038\/s41525-020-00158-5","journal-title":"NPJ Genom Med"},{"key":"ref17","unstructured":"Genetic\/familial high-risk assessment. breast, ovarian, pancreatic, and prostate. (2025). Accessed: July 22, 2025: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bopp.pdf."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early\u00a0breast cancer","volume":"33","author":"Geyer CE Jr","year":"2022","unstructured":"Geyer CE Jr, Garber JE, Gelber RD, et al.. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early\u00a0breast cancer. Ann Oncol. 2022, 33:1250-68. 10.1016\/j.annonc.2022.09.159","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang YJ","year":"2017","unstructured":"Bang YJ, Xu RH, Chin K, et al.. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017, 18:1637-51. 10.1016\/S1470-2045(17)30682-4","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-2620","article-title":"BRCA2 germline mutations identify gastric cancers responsive to PARP inhibitors","volume":"83","author":"Petrelli A","year":"2023","unstructured":"Petrelli A, Rizzolio S, Pietrantonio F, et al.. BRCA2 germline mutations identify gastric cancers responsive to PARP inhibitors. Cancer Res. 2023, 83:1699-710. 10.1158\/0008-5472.CAN-22-2620","journal-title":"Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/369204-linitis-plastica-in-a-patient-with-a-brca2-mutation-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:03:52Z","timestamp":1769547832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/369204-linitis-plastica-in-a-patient-with-a-brca2-mutation-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.102423","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}